Saturday 17 October 2026
Export CYVNY’s income statement to Excel — free account
Ceryvyn Therapeutics Ltd. - Unsponsored ADR
CYVNY Healthcare Biotechnology
Ceryvyn Therapeutics Ltd. - Unsponsored ADR’s revenue for fiscal 2025 (year ended June 2025) was $25,000.00, down 80.0% from fiscal 2024.
0.02
0.00
0.00%
Follow CYVNY
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Jun '25 | Jun '24 | Jun '23 | Jun '22 | Jun '21 | Jun '20 | Jun '19 | Jun '18 | Jun '17 | Jun '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
48.44 | 172.47 | 89.19 | 44.63 | 118.19 | 42.65 | 15.06 | 24.08 | 39.97 | 10.77 |
Receivables |
7.61 | 11.82 | 6.56 | 6.56 | 5.54 | 6.06 | 10.44 | 9.19 | 2.48 | 1.47 |
Other current assets |
0.75 | 3.90 | 2.63 | 8.72 | 14.39 | 0.33 | 0.30 | 0.22 | 0.12 | 0.14 |
Total current assets |
56.80 | 188.19 | 98.39 | 59.91 | 138.12 | 49.04 | 25.80 | 33.49 | 42.56 | 12.38 |
Property, Plant, Equpment (Net) |
— | 0.05 | 0.03 | 0.03 | 0.02 | 0.03 | 0.04 | 0.05 | 0.05 | 0.07 |
Long-Term Investments |
— | — | — | — | — | 0.20 | 0.50 | 0.59 | 0.88 | 0.23 |
Long-term assets (Other) |
— | 0.47 | 0.05 | 0.11 | 0.17 | — | — | — | — | — |
Total non-current assets |
— | 0.60 | 0.26 | 0.14 | 0.29 | 0.39 | — | — | — | — |
Total Assets |
56.80 | 188.79 | 98.64 | 60.05 | 138.41 | 49.44 | 26.34 | 34.13 | — | 12.68 |
Accounts Payable |
9.74 | 38.10 | 17.89 | 11.45 | 2.50 | 4.05 | 4.12 | 5.35 | — | — |
Current Part of Capital Lease |
— | 0.09 | 0.10 | — | 0.11 | 0.10 | — | — | — | — |
Other current liabilities |
248.13 | 25.86 | 0.75 | 0.60 | 0.49 | 0.60 | 0.39 | 0.44 | 1.50 | 1.46 |
Total current liabilities |
257.87 | 64.06 | 18.74 | 12.04 | 3.11 | 4.76 | 4.56 | 5.83 | 1.54 | 1.50 |
Long Term Debt (Total) |
— | 200.54 | 85.74 | — | — | 0.08 | — | — | — | — |
Non-current Liabilities (Other) |
— | 0.01 | 0.01 | 0.03 | 0.02 | 0.03 | 0.02 | 0.03 | 0.04 | 0.05 |
Total non-current liabilities |
— | 200.55 | 85.75 | 0.03 | 0.02 | 0.11 | — | — | — | — |
Total liabilities |
257.87 | 264.60 | 104.49 | 12.07 | 3.12 | 4.87 | 4.57 | 5.85 | 1.58 | 1.54 |
Common Stock (Net) |
497.49 | 466.09 | 320.88 | 235.28 | 234.15 | 113.85 | 79.04 | 72.89 | 75.27 | 40.04 |
Retained Earnings |
(742.49) | (579.70) | (359.46) | (216.94) | (124.12) | (78.78) | (60.18) | (48.26) | (37.11) | (31.27) |
Shareholders Equity (Other) |
43.94 | 37.81 | 32.73 | 29.64 | 25.26 | 9.50 | — | — | — | — |
Common Equity (Total) |
(201.07) | (75.81) | (5.85) | 47.98 | 135.29 | 44.57 | 21.76 | 28.28 | 41.92 | 11.14 |
Shareholders Equity (Total) |
(201.07) | (75.81) | (5.85) | 47.98 | 135.29 | 44.57 | 21.76 | 28.28 | 41.92 | 11.14 |
Shareholders Equity and Liabilities (Total) |
56.80 | 188.79 | 98.64 | 60.05 | 138.41 | 49.44 | — | — | — | — |
Shares (Common) |
153.92 | 136.43 | 58.40 | 44.02 | 43.88 | 33.65 | — | — | — | — |
Shareholders Equity (Tangible) |
(201.07) | (75.81) | (5.85) | 47.98 | 135.29 | 44.57 | — | — | — | — |
Net Debt |
(48.44) | 28.07 | (3.44) | (44.63) | (118.19) | (42.57) | (15.06) | (24.08) | (39.97) | (10.77) |
Total Debt |
— | 200.54 | 85.74 | — | 0.11 | 0.08 | — | — | — | — |
In millions of $ except per-share values · columns are period end dates